These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36745378)

  • 21. Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis.
    Bagel J; Novak K; Nelson E
    Cutis; 2022 Feb; 109(2):103-109. PubMed ID: 35659807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
    Alexis AF; Desai SR; Han G; Jacobson A
    J Drugs Dermatol; 2021 Jul; 20(7):744. PubMed ID: 34232005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 24. An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.
    Ozyurekoglu E; Kircik L
    J Drugs Dermatol; 2021 Nov; 20(11):1191-1194. PubMed ID: 34784123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses.
    Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
    Skin Therapy Lett; 2022 May; 27(3):1-4. PubMed ID: 35533304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report.
    Desai SR; Alexis AF; Jacobson A
    J Drugs Dermatol; 2020 Oct; 19(10):1000-1004. PubMed ID: 33026772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
    Guenther L; Metelitsa A; Prajapati VH
    Skin Therapy Lett; 2021 Nov; 26(6):1-3. PubMed ID: 34871475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
    Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene.
    Kircik L; Bhatia N; Lain E; Jacobson A
    J Drugs Dermatol; 2023 Mar; 22(3):247-251. PubMed ID: 36877884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.
    Del Rosso JQ; Kircik L; Lin T; Pillai R
    J Clin Aesthet Dermatol; 2019 Jan; 12(1):11-15. PubMed ID: 30881571
    [No Abstract]   [Full Text] [Related]  

  • 33. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants.
    Cook-Bolden FE; Hebert AA; Guenthner ST; Kang R; Martin G; Jacobson A
    J Drugs Dermatol; 2020 Aug; 19(8):747-754. PubMed ID: 32845589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.
    Bhatia ND; Pariser DM; Kircik L; Lin T; Harris S; Mathew L; Pillai R
    J Clin Aesthet Dermatol; 2018 Nov; 11(11):15-19. PubMed ID: 30588269
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
    Lebwohl MG; Sugarman JL; Gold LS; Pariser DM; Lin T; Pillai R; Martin G; Harris S; Israel R
    J Am Acad Dermatol; 2019 Jan; 80(1):282-285. PubMed ID: 30227193
    [No Abstract]   [Full Text] [Related]  

  • 36. Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.
    Desai SR; Glick B; Del Rosso JQ; Harris S; Jacobson A
    J Drugs Dermatol; 2021 Mar; 20(3):252-258. PubMed ID: 33683083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial.
    Chen H; Sun J; Yang H; Sun Q; Zhang J; Gu J; Wen H; Li M; Liu X; Yang H; Lou D
    J Dermatol; 2020 Jul; 47(7):728-734. PubMed ID: 32346959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.
    Gupta AK; Love RP; Abramovits W; Vincent KD
    Skinmed; 2019; 17(3):181-183. PubMed ID: 31496472
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
    Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.
    Lebwohl MG; Tanghetti EA; Stein Gold L; Del Rosso JQ; Gilyadov NK; Jacobson A
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1157-1174. PubMed ID: 34106439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.